文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

多价S2亚基疫苗为雌性小鼠提供针对第1进化枝严重急性呼吸综合征冠状病毒的广泛保护。

Multivalent S2 subunit vaccines provide broad protection against Clade 1 sarbecoviruses in female mice.

作者信息

Halfmann Peter J, Patel Raj S, Loeffler Kathryn, Yasuhara Atsuhiro, Van De Velde Lee-Ann, Yang Jie E, Chervin Jordan, Troxell Chloe, Huang Min, Zheng Naiying, Wright Elizabeth R, Thomas Paul G, Wilson Patrick C, Kawaoka Yoshihiro, Kane Ravi S

机构信息

Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI, USA.

Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA.

出版信息

Nat Commun. 2025 Jan 7;16(1):462. doi: 10.1038/s41467-025-55824-y.


DOI:10.1038/s41467-025-55824-y
PMID:39774966
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11706982/
Abstract

The continuing emergence of immune evasive SARS-CoV-2 variants and the previous SARS-CoV-1 outbreak collectively underscore the need for broadly protective sarbecovirus vaccines. Targeting the conserved S2 subunit of SARS-CoV-2 is a particularly promising approach to elicit broad protection. Here, we describe a nanoparticle vaccine displaying multiple copies of the SARS-CoV-1 S2 subunit. This vaccine alone, or as a cocktail with a SARS-CoV-2 S2 subunit vaccine, protects female transgenic K18-hACE2 mice from challenges with Omicron subvariant XBB as well as several sarbecoviruses identified as having pandemic potential including the bat sarbecovirus WIV1, BANAL-236, and a pangolin sarbecovirus. Challenge studies in female Fc-γ receptor knockout mice reveal that antibody-based cellular effector mechanisms play a role in protection elicited by these vaccines. These results demonstrate that our S2-based vaccines provide broad protection against clade 1 sarbecoviruses and offer insight into the mechanistic basis for protection.

摘要

免疫逃逸的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变异株持续出现,以及之前的SARS-CoV-1疫情,共同凸显了研发具有广泛保护作用的沙贝病毒疫苗的必要性。靶向SARS-CoV-2保守的S2亚基是一种特别有前景的引发广泛保护的方法。在此,我们描述了一种展示多个SARS-CoV-1 S2亚基拷贝的纳米颗粒疫苗。这种疫苗单独使用,或与SARS-CoV-2 S2亚基疫苗混合使用,可保护雌性转基因K18-hACE2小鼠免受奥密克戎变异株XBB以及几种被确定具有大流行潜力的沙贝病毒(包括蝙蝠沙贝病毒WIV1、BANAL-236和穿山甲沙贝病毒)的攻击。对雌性Fc-γ受体敲除小鼠的攻毒研究表明,基于抗体的细胞效应机制在这些疫苗引发的保护中发挥作用。这些结果表明,我们基于S2的疫苗可对第1进化枝沙贝病毒提供广泛保护,并为保护的机制基础提供了见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7d7/11706982/5c05eaff6335/41467_2025_55824_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7d7/11706982/301994015a5d/41467_2025_55824_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7d7/11706982/58cc32537953/41467_2025_55824_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7d7/11706982/3d5850de479c/41467_2025_55824_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7d7/11706982/a209f4e178a3/41467_2025_55824_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7d7/11706982/460f7b41cb6b/41467_2025_55824_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7d7/11706982/5c05eaff6335/41467_2025_55824_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7d7/11706982/301994015a5d/41467_2025_55824_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7d7/11706982/58cc32537953/41467_2025_55824_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7d7/11706982/3d5850de479c/41467_2025_55824_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7d7/11706982/a209f4e178a3/41467_2025_55824_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7d7/11706982/460f7b41cb6b/41467_2025_55824_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7d7/11706982/5c05eaff6335/41467_2025_55824_Fig6_HTML.jpg

相似文献

[1]
Multivalent S2 subunit vaccines provide broad protection against Clade 1 sarbecoviruses in female mice.

Nat Commun. 2025-1-7

[2]
Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge.

J Virol. 2024-9-17

[3]
A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines.

Nat Commun. 2024-6-28

[4]
MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses.

Front Immunol. 2024

[5]
Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters.

J Virol. 2024-10-22

[6]
A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.

J Virol. 2022-9-14

[7]
Early 2022 breakthrough infection sera from India target the conserved cryptic class 5 epitope to counteract immune escape by SARS-CoV-2 variants.

J Virol. 2025-4-15

[8]
A SARS-CoV and SARS-CoV-2 RBD Heterodimer Vaccine Candidate.

J Med Virol. 2025-5

[9]
Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variants.

Emerg Microbes Infect. 2024-12

[10]
Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain.

J Virol. 2024-9-17

引用本文的文献

[1]
Adaptation of the Vaccine Prophylaxis Strategy to Variants of the SARS-CoV-2 Virus.

Vaccines (Basel). 2025-7-17

[2]
Merbecovirus S2 subunit vaccines elicit cross reactive antibodies and provide partial protection against MERS coronavirus.

Npj Viruses. 2025-7-29

本文引用的文献

[1]
Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination.

Cell Rep. 2024-11-26

[2]
A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines.

Nat Commun. 2024-6-28

[3]
Prefusion-stabilized SARS-CoV-2 S2-only antigen provides protection against SARS-CoV-2 challenge.

Nat Commun. 2024-2-20

[4]
Broad protection against clade 1 sarbecoviruses after a single immunization with cocktail spike-protein-nanoparticle vaccine.

Nat Commun. 2024-2-12

[5]
Engineered immunogens to elicit antibodies against conserved coronavirus epitopes.

Nat Commun. 2023-11-30

[6]
HR121 targeting HR2 domain in S2 subunit of spike protein can serve as a broad-spectrum SARS-CoV-2 inhibitor intranasal administration.

Acta Pharm Sin B. 2023-5-26

[7]
Fc-mediated pan-sarbecovirus protection after alphavirus vector vaccination.

Cell Rep. 2023-4-25

[8]
Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron.

Cytokine Growth Factor Rev. 2023-4

[9]
Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease.

Immunity. 2023-3-14

[10]
A Preliminary Study in Immune Response of BALB/c and C57BL/6 Mice with a Locally Allergic Rhinitis Model.

Am J Rhinol Allergy. 2023-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索